marax oral liquid - search results

organon llc - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41) - fosamax® plus d is indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, fosamax plus d increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [see clinical studies (14.1).] fosamax plus d is indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.2)]. fosamax plus d alone should not be used to treat vitamin d deficiency. the optimal duration of use has not been determined. the safety and effectiveness of fosamax plus d for the treatment of osteoporosis are based on clinical data of four years duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. fosamax plus d is contraindicated in

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

fosamax once weekly 70mg tablets

waymade healthcare plc - alendronate sodium - oral tablet - 70mg